LSL Pharma Group Inc.
LSL.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 50.18% | 51.15% | 94.80% | 84.26% | 49.48% |
| Total Depreciation and Amortization | 0.31% | 17.57% | 34.55% | -17.88% | 35.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.48% | 95.82% | -87.42% | -154.73% | 21.72% |
| Change in Net Operating Assets | 78.79% | -290.25% | 23.34% | -265.48% | -1,113.60% |
| Cash from Operations | 96.47% | -1,267.16% | 58.92% | 59.51% | -267.47% |
| Capital Expenditure | -532.23% | -296.55% | -361.93% | 85.85% | 1.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -558.06% | -1,905.41% | -485.41% | 22.82% | -- |
| Cash from Investing | -549.27% | -1,223.78% | -383.44% | 222.23% | -11.17% |
| Total Debt Issued | -40.27% | -47.54% | 214.50% | -97.22% | 969.92% |
| Total Debt Repaid | -480.00% | -229.94% | 84.63% | 1,525.61% | 68.51% |
| Issuance of Common Stock | -- | -- | -79.02% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | 99.97% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 40.74% | -84.82% | 83.07% | -23.52% | -197.20% |
| Cash from Financing | -36.33% | -- | -53.80% | -83.56% | 183.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 77.46% | 236.80% | -105.51% | 144.17% | -389.52% |
